#1 Clinical Trials Search in Europe

Pyrazinamide

Pyrazinamide is an important antibiotic used in the treatment of tuberculosis (TB). This article examines several clinical trials investigating pyrazinamide as part of new combination therapies and treatment regimens for TB. These studies aim to improve TB treatment by shortening duration, increasing efficacy, and addressing drug-resistant strains.

Table of Contents

What is Pyrazinamide?

Pyrazinamide, also known as PZA, is an important antibiotic medication used in the treatment of tuberculosis (TB). It is considered a first-line drug in the fight against TB, which is a serious bacterial infection that primarily affects the lungs[1]. Pyrazinamide plays a crucial role in shortening the course of TB treatment and helping to clear the bacteria from the body more effectively[1].

How Pyrazinamide Works

Pyrazinamide works by killing or stopping the growth of the bacteria that cause tuberculosis. It is particularly effective against Mycobacterium tuberculosis, the bacterium responsible for TB. This medication is unique because it can kill TB bacteria that are in a dormant or slow-growing state, which other TB drugs may not be able to target as effectively[2].

Conditions Treated with Pyrazinamide

Pyrazinamide is primarily used to treat:

  • Pulmonary Tuberculosis: This is the most common form of TB that affects the lungs[3].
  • Multidrug-Resistant Tuberculosis (MDR-TB): A form of TB that is resistant to at least two of the most powerful first-line TB drugs[1].
  • Drug-Resistant Tuberculosis: TB that has developed resistance to one or more TB medications[4].

Dosage and Administration

The dosage of pyrazinamide can vary depending on the patient’s weight and the specific treatment regimen. Generally, it is taken orally (by mouth) once daily. Here are some common dosage ranges:

  • For adults weighing 33-50 kg: 1000-1750 mg daily
  • For adults weighing 51-70 kg: 1750-2000 mg daily
  • For adults weighing over 70 kg: 2000-2500 mg daily[1]

It’s important to note that pyrazinamide is usually prescribed as part of a combination therapy and should be taken exactly as directed by your healthcare provider[3].

Pyrazinamide in Combination Therapy

Pyrazinamide is typically used in combination with other TB medications to create a more effective treatment regimen. Some common combinations include:

  • HRZE: Isoniazid (H), Rifampin (R), Pyrazinamide (Z), and Ethambutol (E). This is a standard first-line treatment for TB[5].
  • BPaMZ: Bedaquiline (B), Pretomanid (Pa), Moxifloxacin (M), and Pyrazinamide (Z). This combination is being studied for drug-resistant TB[4].
  • BCZD: Bedaquiline (B), Clofazimine (C), Pyrazinamide (Z), and Delamanid (D). This is an experimental regimen being studied for shorter TB treatment duration[6].

Safety and Side Effects

While pyrazinamide is generally well-tolerated, it can cause side effects in some patients. Common side effects may include:

  • Nausea and vomiting
  • Loss of appetite
  • Joint pain
  • Skin rash
  • Fatigue

More serious side effects, though rare, can include liver problems. Your doctor will monitor your liver function while you’re taking pyrazinamide[7]. If you experience symptoms such as yellowing of the skin or eyes, dark urine, or persistent nausea, contact your healthcare provider immediately.

Ongoing Research and Clinical Trials

Researchers are continuously studying pyrazinamide to improve its use in TB treatment. Some areas of ongoing research include:

  • Optimizing dosage and treatment duration to improve efficacy and reduce side effects[3].
  • Investigating new drug combinations that include pyrazinamide for more effective and shorter TB treatments[6].
  • Studying the use of pyrazinamide in treating drug-resistant TB[1].
  • Evaluating the safety of pyrazinamide when used in combination with newer TB drugs[4].

These ongoing studies aim to improve TB treatment outcomes and potentially shorten the duration of therapy, which could lead to better patient adherence and reduced risk of developing drug resistance[6].

Study Focus Key Drugs Duration Main Outcomes
Optimizing MDR-TB treatment Pyrazinamide, Amikacin, Levofloxacin, Clarithromycin, Prothionamide 12-24 months Sputum culture conversion, adverse events
Pyrazinamide with Allopurinol Pyrazinamide, Allopurinol 8 days Whole blood bactericidal activity, pharmacokinetics
High-dose Rifampicin and Pyrazinamide Rifampicin, Pyrazinamide, Isoniazid, Ethambutol 4-6 months Pharmacokinetics, safety, sputum culture conversion
Ultra-short TB regimen Bedaquiline, Clofazimine, Pyrazinamide, Delamanid 12 weeks Time to culture conversion, safety, treatment success
Celecoxib with TB drugs Celecoxib, Rifampicin, Pyrazinamide 3 visits Whole blood bactericidal activity, pharmacokinetics

FAQ

  • What is pyrazinamide and how is it used to treat tuberculosis? Pyrazinamide is an antibiotic medication used as part of combination therapy to treat tuberculosis. It works by killing or stopping the growth of tuberculosis bacteria. Pyrazinamide is typically given along with other TB drugs for the first 2 months of treatment.
  • Why are researchers studying new treatment regimens that include pyrazinamide? Researchers are studying new regimens with pyrazinamide to try to shorten overall treatment duration, improve efficacy against drug-resistant TB strains, and reduce side effects. The goal is to develop more effective and tolerable TB treatments.
  • What are some of the other drugs being studied in combination with pyrazinamide? Some of the other drugs being studied with pyrazinamide in clinical trials include bedaquiline, clofazimine, delamanid, moxifloxacin, rifapentine, and high-dose rifampicin. These combinations aim to create more potent TB regimens.
  • How long do the pyrazinamide-containing regimens typically last in these trials? The pyrazinamide-containing regimens in these trials range from 12 weeks to 6 months in duration. This is shorter than the standard 6-9 month TB treatment, as researchers aim to reduce overall treatment time.
  • What are some of the main outcomes being measured in these pyrazinamide clinical trials? Key outcomes being measured include time to sputum culture conversion, treatment success rates, safety and tolerability, pharmacokinetics of the drugs, and development of drug resistance. Some trials also look at long-term outcomes like relapse rates.

Ongoing Clinical Trials on Pyrazinamide

  • Study evaluating blood biomarkers for diagnosis and monitoring treatment in patients with pulmonary tuberculosis using isoniazid, rifampicin, pyrazinamide, and ethambutol combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on High-Dose Rifampicin Safety for Adults with Complex Tuberculosis Using Isoniazid, Pyrazinamide, and Ethambutol Combination

    Recruiting

    1 1 1
    Investigated drugs:
    The Netherlands Spain

  • Study on the Effects of Tedizolid and Linezolid for Patients with Suspected Lung Tuberculosis

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on Higher Doses of Rifampicin and Pyrazinamide for Shortened Treatment of Mild-to-Moderate Tuberculosis in Patients with Drug-Sensitive Pulmonary TB

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on the Effectiveness and Safety of High-Dose Rifampicin, Moxifloxacin, and Linezolid for Patients with Pulmonary Tuberculosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Tuberculosis (TB): An infectious disease caused by Mycobacterium tuberculosis bacteria that primarily affects the lungs but can also impact other parts of the body.
  • Multidrug-resistant tuberculosis (MDR-TB): A form of TB that is resistant to at least isoniazid and rifampicin, two of the most powerful first-line TB drugs.
  • Sputum culture conversion: When a patient's sputum sample changes from testing positive for TB bacteria to testing negative, indicating the treatment is working.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Whole blood bactericidal activity (WBA): A laboratory test that measures how effectively a patient's blood can kill TB bacteria after taking anti-TB medications.
  • Adverse event (AE): Any unfavorable and unintended sign, symptom, or disease that occurs during treatment, which may or may not be related to the medication.
  • QTcF interval: A measurement of the heart's electrical cycle, used to monitor for potential cardiac side effects of certain medications.
  • Minimum inhibitory concentration (MIC): The lowest concentration of an antibiotic that prevents visible growth of bacteria.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body and how they relate to drug concentration.
  • Time to positivity (TTP): A measure of how quickly TB bacteria grow in a culture, used to assess the effectiveness of TB treatment.

References

  1. https://clinicaltrials.gov/study/NCT02120638
  2. https://clinicaltrials.gov/study/NCT02602509
  3. https://clinicaltrials.gov/study/NCT04694586
  4. https://clinicaltrials.gov/study/NCT04179500
  5. https://clinicaltrials.gov/study/NCT00728507
  6. https://clinicaltrials.gov/study/NCT05556746
  7. https://clinicaltrials.gov/study/NCT01395654